Skip to main content
. Author manuscript; available in PMC: 2018 May 1.
Published in final edited form as: Cancer Res. 2017 Mar 30;77(9):2207–2212. doi: 10.1158/0008-5472.CAN-16-2503

Figure 3.

Figure 3

A, nascent RNA in LREX’ cells treated with ARE-1 for 48hours. Actinomycin D (Act D):positive control. B, nascent RNA in LREX’ cells by flow cytometry after treatment with 10μM ARE-1 for 24, 48, 72hours. C, composite of flow cytometry results. Error bars are SEM. *p<0.05; **p<0.005; ***p<0.0005.